Shingo Harita

1.1k total citations
52 papers, 790 citations indexed

About

Shingo Harita is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Shingo Harita has authored 52 papers receiving a total of 790 indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 18 papers in Molecular Biology. Recurrent topics in Shingo Harita's work include Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Research Studies (28 papers) and Cancer therapeutics and mechanisms (16 papers). Shingo Harita is often cited by papers focused on Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Research Studies (28 papers) and Cancer therapeutics and mechanisms (16 papers). Shingo Harita collaborates with scholars based in Japan, India and Greece. Shingo Harita's co-authors include Katsuyuki Kiura, Mitsune Tanimoto, Katsuyuki Hotta, Nagio Takigawa, Hiroshi Ueoka, Masahiro Tabata, Yoshihiko Segawa, Takuo Shibayama, Akihiro Bessho and Toshiro Yonei and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

Shingo Harita

49 papers receiving 752 citations

Peers

Countries citing papers authored by Shingo Harita

Since Specialization

Citations

This map shows the geographic impact of Shingo Harita's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shingo Harita with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shingo Harita more than expected).

Fields of papers citing papers by Shingo Harita

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shingo Harita. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shingo Harita. The network helps show where Shingo Harita may publish in the future.

Co-authorship network of co-authors of Shingo Harita

This figure shows the co-authorship network connecting the top 25 collaborators of Shingo Harita. A scholar is included among the top collaborators of Shingo Harita based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shingo Harita. Shingo Harita is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression 2021 ·European Journal of Cancer ·Nobuaki Ochi, Eiki Ichihara, Nagio Takigawa, Daijiro Harada, Koji Inoue, Takuo Shibayama, Shinobu Hosokawa, Daizo Kishino, Shingo Harita, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura	43
2	Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors 2020 ·Cancer Immunology Immunotherapy ·Eiki Ichihara, Daijiro Harada, Koji Inoue, Takuo Shibayama, Shinobu Hosokawa, Daizo Kishino, Shingo Harita, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura	28
3	A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403 2018 ·Cancer Chemotherapy and Pharmacology ·Naohiro Oda, (unknown), Kiichiro Ninomiya, Daisuke Minami, Eiki Ichihara, (unknown), Toshihide Yokoyama, (unknown), Kenichi Chikamori, Nagio Takigawa, Nobuaki Ochi, Shingo Harita, Yoshinobu Maeda, Katsuyuki Kiura	20
4	Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403 2016 ·Clinical Lung Cancer ·Naohiro Oda, Eiki Ichihara, Katsuyuki Hotta, Kiichiro Ninomiya, Takashi Ninomiya, Toshio Kubo, Daisuke Minami, (unknown), Toshihide Yokoyama, Daijiro Harada, Shoichi Kuyama, (unknown), Koji Inoue, Daizo Kishino, Masaaki Inoue, Nagio Takigawa, Takuo Shibayama, Shingo Harita, Mitsune Tanimoto, Katsuyuki Kiura	8
5	[HER2-Positive Advanced Gastric Cancer with Disseminated Intravascular Coagulation and Diffuse Bone Marrow Carcinomatosis Successfully Treated with S-1/Trastuzumab Chemotherapy--A Case Report]. 2015 ·PubMed ·Satoru Senoo, Tomohiko Mannami, Tomoki Tamura, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Takeshi Kambara, (unknown), (unknown), (unknown), Toshiaki Okada, Shingo Harita, Hiroshi Sonobe	2
6	A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705 2010 ·Journal of Thoracic Oncology ·Hiroshige Yoshioka, Katsuyuki Hotta, Katsuyuki Kiura, Nagio Takigawa, Hidetoshi Hayashi, Shingo Harita, Shoichi Kuyama, Yoshihiko Segawa, Haruhito Kamei, Shigeki Umemura, Akihiro Bessho, Masahiro Tabata, Mitsune Tanimoto	56
7	Effect of Long-Term and Low-Dose Administration of Erythromycin on Proliferation of T Lymphocytes 2008 ·Journal of Chemotherapy ·Shingo Harita, Shoichi Kuyama, Toshikazu Okada, Yoshiro Tanizaki	3
8	A Case of Pulmonary Adenocarcinoma Followed by Computed Tomography for 11 Years 2007 ·Haigan ·Takashi Yoshioka, Shingo Harita, Shoichi Kuyama, Naoyuki Nogami	3
9	A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer 2007 ·Cancer Chemotherapy and Pharmacology ·Masahiro Tabata, Katsuyuki Kiura, Niro Okimoto, Yoshihiko Segawa, Tetsu Shinkai, Toshiro Yonei, Shoichi Kuyama, Shingo Harita, Katsuyuki Hotta, Hiroshi Ueoka, Mitsune Tanimoto	3
10	A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study 2006 ·Cancer Chemotherapy and Pharmacology ·Masahiro Tabata, Toshiyuki Kozuki, Hiroshi Ueoka, Katsuyuki Kiura, Shingo Harita, Atsuhiko Tada, Takuo Shibayama, Nagio Takigawa, Toshiro Yonei, Kenichi Gemba, Yoshihiko Segawa, Daizo Kishino, Shinya Tada, Shunkichi Hiraki, Mitsune Tanimoto, (unknown)	2
11	A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer 2006 ·Lung Cancer ·Takuo Shibayama, Katsuyuki Hotta, Nagio Takigawa, Atsuhiko Tada, Hiroshi Ueoka, Shingo Harita, Katsuyuki Kiura, Masahiro Tabata, Yoshihiko Segawa, Naoyuki Nogami, Shoichi Kuyama, Tetsu Shinkai, Mitsune Tanimoto	10
12	Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience 2005 ·Annals of Oncology ·Katsuyuki Hotta, Keitaro Matsuo, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Shingo Harita, Kenichi Gemba, (unknown), Akihiro Bessho, Mitsune Tanimoto	21
13	Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group Experience 2005 ·Acta Oncologica ·Katsuyuki Hotta, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Atsuko Ogino, Shigeki Umemura, Shingo Harita, Kenichi Gemba, Toshiro Yonei, Akihiro Bessho, Tadashi Maeda, Mitsune Tanimoto	18
14	Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only 2005 ·International Journal of Clinical Oncology ·Shingo Harita, (unknown), Shoichi Kuyama, Takeshi Kikuchi	12
15	Interstitial Lung Disease in Japanese Patients With Non-Small Cell Lung Cancer Receiving Gefitinib 2005 ·The Cancer Journal ·Katsuyuki Hotta, Katsuyuki Kiura, Masahiro Tabata, Shingo Harita, Kenichi Gemba, Toshiro Yonei, Akihiro Bessho, Tadashi Maeda, Tomonori Moritaka, Takuo Shibayama, Keisuke Matsuo, Katsuya Kato, Arihiko Kanehiro, Yasushi Tanimoto, Keitaro Matsuo, Hiroshi Ueoka, Mitsune Tanimoto	62
16	Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer 2004 ·Lung Cancer ·Naoyuki Nogami, Shingo Harita, Hiroshi Ueoka, Toshiro Yonei, Katsuyuki Kiura, Haruhito Kamei, Masahiro Tabata, Yoshihiko Segawa, Kenichi Gemba, Mitsune Tanimoto	6
17	Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer 2003 ·British Journal of Cancer ·(unknown), Katsuyuki Kiura, Hiroshi Ueoka, Yoshihiko Segawa, (unknown), (unknown), Nagio Takigawa, Shunkichi Hiraki, Yoichi Watanabe, Akihiro Bessho, K. Eguchi, Niro Okimoto, Shingo Harita, Mitsuhiro Takemoto, Yoshio Hiraki, M Harada, Mitsune Tanimoto	56
18	[Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer]. 2002 ·PubMed ·Atsuhiko Tada, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Mitsuhiro Takemoto, Hiromichi Yamane, (unknown), Keisuke Aoe, Takuo Shibayama, Haruhito Kamei, (unknown), Shingo Harita, Toshio Sato, Makoto Kobayashi, Kenji Eguchi, Shunkichi Hiraki, Yoshio Hiraki, Mitsune Tanimoto	1
19	A difficult diagnosis? 2002 ·The Lancet Oncology ·(unknown), (unknown), (unknown), Shingo Harita, (unknown), (unknown), (unknown)	0
20	Preliminary evaluation of soluble IL‐2 receptor and type III procollagen N‐terminal aminopeptide in pleural fluid for differentiating tuberculous, carcinomatous and parapneumonic pleural effusions 2002 ·Respirology ·Shingo Harita, Naoyuki Nogami, Takeshi Kikuchi, Masayoshi Kibata	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact